A new lung cancer treatment for patients who have a specific tumour mutation has received a positive opinion in Europe. The drug, Tagrisso (osimertinib), was developed by AstraZeneca Plc. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
